Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal

 
• By Jessica Merrill

Biogen agreed to pay $300m upfront to buy a Phase II-ready tau antibody from Bristol. The plan is to move rapidly into mid-stage clinical trials for Alzheimer's disease and progressive supranuclear palsy.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Deals

More from Business